Foghorn Therapeutics

🇺🇸United States

Introduction: Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors

Phase 1

Terminated

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Miami Health System, Miami, Florida, United States
🇺🇸
City of Hope, Duarte, California, United States

Phase 1

Active, not recruiting

Conditions: Relapsed Chronic Myelomonocytic Leukemia
Advanced Hematologic Malignancy
Relapsed Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Refractory Chronic Myelomonocytic Leukemia
Relapsed Myelodysplastic Syndromes
Refractory Myelodysplastic Syndromes

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Phase 1

Terminated

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
🇺🇸
University of Miami Health System, Sylvester Comprehensive Cancer Center, Miami, Florida, United States